Biomedical company Polaris Group (北極星) yesterday said that it would continue developing its cancer treatment ADI-PEG 20, but with a new approach, following a setback in a clinical trial.
A phase III study of the effectiveness of ADI-PEG 20 as a second-line treatment for hepatocellular carcinoma (HCC) failed to demonstrate overall survival (OS) benefits, the company said in a statement on June 6.
The study showed that median OS was 7.8 months for patients receiving ADI-PEG 20, which was not significantly better than the 7.4 months for patients given a placebo.
Polaris Group chief executive officer Wu Bor-wen (吳伯文) told an investors’ conference that despite the setback, the company has formed a solid plan moving forward from the clinical trial.
ADI-PEG 20 is arginine deiminase (ADI) formulated with polyethylene glycol, with an average molecular weight of 20 kilodaltons (PEG 20), and the treatment is designed to degrade arginine, an amino acid crucial to tumor cell metabolism and the growth of certain cancers, Wu said.
An analysis of the clinical trial data showed that patients with arginine depletion for seven weeks or longer had a median OS of 12.5 months, compared with 6.3 months for patients with arginine depletion of less than seven weeks, Wu said.
“This outcome shows that the treatment is effective against cancer, as arginine-starved cancer cells are unable to survive and grow,” Wu said.
In addition, Wu said the study showed that ADI-PEG 20 was more beneficial for patients who have never had prior treatment with Nexarvar, a sorafenib-based drug for treating diseases including kidney and liver cancer, and thyroid carcinoma.
For some patients, prior treatment with Nexarvar reduced the arginine deprivation ability of ADI-PEG 20, and the company’s new treatment might be more effective as a first-line treatment, Wu said.
Nexarvar induces argininosuccinate synthase (ASS) expression, an enzyme that catalyzes the synthesis of argininosuccinate from citrulline and aspartate, which makes ADI-PEG 20 ineffective as a monotherapy option, Wu said.
The company said it would explore alternative roles for ADI-PEG 20, such as using the treatment as a component of combination therapy as a first-line treatment, as well as using higher dosages to promote longer arginine depletion, Wu said.
Wu added that in March, the firm began a number of clinical trials for ADI-PEG 20 on treating mesothelioma of the lungs and pancreatic cancer, and that regulatory approval for one of the indications might come in about 2018.
To obtain market approval, the company is to file biologics license applications with regulators, and expand its sales potential by testing more ASS-deficient tumors in trials, Wu said.
Combination research is becoming more common in new cancer drug development, but testing each combination candidate would require a tremendous amount of time, Polaris Group medical affairs executive vice president John Bomalaski said.
The company will also improve patient selection so that those who are more likely to benefit from ADI-PEG 20 are included in future clinical trials, Bomalaski said.
CHIP WAR: Tariffs on Taiwanese chips would prompt companies to move their factories, but not necessarily to the US, unleashing a ‘global cross-sector tariff war’ US President Donald Trump would “shoot himself in the foot” if he follows through on his recent pledge to impose higher tariffs on Taiwanese and other foreign semiconductors entering the US, analysts said. Trump’s plans to raise tariffs on chips manufactured in Taiwan to as high as 100 percent would backfire, macroeconomist Henry Wu (吳嘉隆) said. He would “shoot himself in the foot,” Wu said on Saturday, as such economic measures would lead Taiwanese chip suppliers to pass on additional costs to their US clients and consumers, and ultimately cause another wave of inflation. Trump has claimed that Taiwan took up to
A start-up in Mexico is trying to help get a handle on one coastal city’s plastic waste problem by converting it into gasoline, diesel and other fuels. With less than 10 percent of the world’s plastics being recycled, Petgas’ idea is that rather than letting discarded plastic become waste, it can become productive again as fuel. Petgas developed a machine in the port city of Boca del Rio that uses pyrolysis, a thermodynamic process that heats plastics in the absence of oxygen, breaking it down to produce gasoline, diesel, kerosene, paraffin and coke. Petgas chief technology officer Carlos Parraguirre Diaz said that in
SUPPORT: The government said it would help firms deal with supply disruptions, after Trump signed orders imposing tariffs of 25 percent on imports from Canada and Mexico The government pledged to help companies with operations in Mexico, such as iPhone assembler Hon Hai Precision Industry Co (鴻海精密), also known as Foxconn Technology Group (富士康科技集團), shift production lines and investment if needed to deal with higher US tariffs. The Ministry of Economic Affairs yesterday announced measures to help local firms cope with the US tariff increases on Canada, Mexico, China and other potential areas. The ministry said that it would establish an investment and trade service center in the US to help Taiwanese firms assess the investment environment in different US states, plan supply chain relocation strategies and
Japan intends to closely monitor the impact on its currency of US President Donald Trump’s new tariffs and is worried about the international fallout from the trade imposts, Japanese Minister of Finance Katsunobu Kato said. “We need to carefully see how the exchange rate and other factors will be affected and what form US monetary policy will take in the future,” Kato said yesterday in an interview with Fuji Television. Japan is very concerned about how the tariffs might impact the global economy, he added. Kato spoke as nations and firms brace for potential repercussions after Trump unleashed the first salvo of
RSS